Valproic acid - Cereno Scientific
Alternative Names: CS-1Latest Information Update: 07 Oct 2024
Price :
$50 *
At a glance
- Originator Cereno Scientific
- Class Anti-ischaemics; Antiarrhythmics; Antiepileptic drugs; Antimigraines; Antithrombotics; Cardiovascular therapies; Nootropics; Pentanoic acids; Small molecules; Vascular disorder therapies
- Mechanism of Action 4-aminobutyrate transaminase inhibitors; Glutamate decarboxylase stimulants; Histone deacetylase inhibitors; Neurotransmitter modulators; Plasminogen activator inhibitor-1 inhibitors; Plasminogen activators; Sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Pulmonary arterial hypertension
- No development reported Stroke; Thrombosis; Venous thromboembolism
Most Recent Events
- 28 Sep 2024 Adverse events data from a phase IIa trial in Pulmonary arterial hypertension released by Cereno Scientific
- 01 Aug 2024 Cereno Scientific completes a phase IIa trial for Pulmonary arterial hypertension in USA and Sweden (PO) (NCT05224531)
- 20 Mar 2024 Cereno Scientific AB initiates an expanded-access trial for Pulmonary arterial hypertension in Sweden (NCT06321705)